Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder among women of reproductive age, affecting an estimated 5–15% of this population globally. It is a leading cause of infertility due to anovulation—failure to ovulate regularly or at all. Women with PCOS often present with irregular menstrual cycles, hyperandrogenism (elevated male hormones), and polycystic ovarian morphology on ultrasound. The anovulatory infertility associated with PCOS poses a significant challenge, but several treatment options exist, with clomiphene citrate historically serving as the first-line pharmacologic intervention. This article provides a comprehensive, evidence-based review of the effectiveness of clomiphene citrate in treating PCOS-related infertility, including its mechanism, clinical outcomes, factors influencing success, monitoring protocols, side effects, and alternative therapies.

Understanding PCOS and Anovulatory Infertility

PCOS is characterized by a complex interplay of hormonal imbalances, including luteinizing hormone (LH) hypersecretion, increased ovarian androgen production, and peripheral insulin resistance with compensatory hyperinsulinemia. These disruptions impair follicular development and prevent the selection and maturation of a dominant follicle, resulting in chronic anovulation. Without ovulation, pregnancy cannot occur naturally. The disorder is diagnosed based on the Rotterdam criteria, requiring at least two of three features: oligo‑ or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovaries on ultrasound.

Infertility affects approximately 70–80% of women with PCOS. While lifestyle modifications—such as weight loss, dietary changes, and increased physical activity—can restore ovulation in some women, many require pharmacologic ovulation induction. Clomiphene citrate has been the mainstay of such therapy for more than five decades, though recent evidence has positioned letrozole as a strong alternative. Nevertheless, clomiphene remains widely used due to its low cost, oral administration, and well‑characterized safety profile.

Mechanism of Action of Clomiphene Citrate

Estrogen Receptor Antagonism in the Hypothalamus

Clomiphene citrate is a selective estrogen receptor modulator (SERM) that acts primarily as an antagonist at estrogen receptors in the hypothalamus and pituitary gland. By blocking the negative feedback effects of circulating estrogen on gonadotropin‑releasing hormone (GnRH) secretion, clomiphene increases the amplitude and frequency of GnRH pulses. This stimulates the anterior pituitary to release greater amounts of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). The elevation in FSH promotes ovarian follicular recruitment and growth, and the midcycle surge of LH triggers final follicular maturation and ovulation.

Regimen and Timing

Clomiphene is typically administered orally at a starting dose of 50 mg daily for five days, beginning on cycle day 3–5 (after a spontaneous or progestin‑induced withdrawal bleed). If ovulation is not achieved, the dose may be increased in subsequent cycles to 100 mg or, rarely, 150 mg per day. Ovulation usually occurs 5–10 days after the last dose. Monitoring through urinary LH detection kits, basal body temperature charting, or mid‑luteal serum progesterone levels can confirm ovulation. Ultrasound monitoring is also used to track follicular growth and assess endometrial thickness, as clomiphene can cause thinning of the endometrium, which may reduce implantation rates.

Ovulation Induction Rates

Clomiphene citrate is effective in inducing ovulation in a high proportion of women with PCOS. Large observational studies and randomized trials consistently report ovulation rates of 60–85% when used at doses up to 150 mg daily. For example, a landmark study by Legro et al. (2007) in the New England Journal of Medicine found an ovulation rate of approximately 49% after letrozole treatment compared to 21% with clomiphene; however, subsequent meta‑analyses that included more recent trials have shown letrozole to be superior in terms of both ovulation and live birth rates. Nonetheless, clomiphene remains effective, particularly in women who are not obese and who have no additional infertility factors.

Pregnancy and Live Birth Rates

Among women with PCOS who ovulate on clomiphene, cycle‑specific pregnancy rates are generally 15–20% per ovulatory cycle. Cumulative pregnancy rates after 6–9 cycles reach approximately 50–60%. The discrepancy between high ovulation rates and lower pregnancy rates is partly explained by clomiphene’s anti‑estrogenic effects on the endometrium and cervical mucus, which can hinder implantation and sperm transport. Additionally, many women with PCOS have coexisting metabolic abnormalities, such as insulin resistance, that impair fertility independently of ovulation status.

Comparison with Other Agents

The Pregnancy in Polycystic Ovary Syndrome (PPCOS) I and II trials, along with numerous systematic reviews, have established letrozole (an aromatase inhibitor) as a more effective first‑line agent for ovulation induction in PCOS. Letrozole produces higher live birth rates (approximately 27–28% vs. 19–20% with clomiphene), lower multiple pregnancy rates, and a better side‑effect profile. Consequently, major guidelines—including those from the American Society for Reproductive Medicine (ASRM) and the Endocrine Society—now recommend letrozole as the initial pharmacotherapy for anovulatory infertility in PCOS. However, clomiphene remains an appropriate option for women who do not have access to letrozole or who prefer its longer history of use and familiarity.

Factors Influencing Success with Clomiphene

Age and Ovarian Reserve

Maternal age is a critical determinant of fertility outcomes across all treatments. Younger women (< 35 years) with PCOS have higher pregnancy and live birth rates with clomiphene than older women, whose ovarian reserve declines and oocyte quality diminishes. Anti‑Müllerian hormone (AMH) levels, which are often elevated in PCOS due to the increased number of small antral follicles, can paradoxically indicate a vigorous response but also predict higher risk of ovarian hyperstimulation syndrome (OHSS) if used with gonadotropins. Very high AMH levels are associated with lower ovulation success rates with clomiphene alone, possibly due to greater follicular arrest.

Body Mass Index (BMI) and Metabolic Factors

Obesity is prevalent in PCOS and worsens insulin resistance, hyperandrogenism, and anovulation. The effectiveness of clomiphene is inversely related to BMI. Women with a BMI > 30 kg/m² have significantly lower ovulation (30–40% less) and pregnancy rates compared to those with normal weight. Weight loss of 5–10% can restore spontaneous ovulation in some women and enhance response to clomiphene. Insulin resistance, even in non‑obese women, also blunts clomiphene efficacy. The addition of metformin (an insulin sensitizer) has been studied but yields only modest improvements in ovulation and pregnancy rates when combined with clomiphene; current guidelines do not recommend routine metformin use for ovulation induction except in women with prediabetes or metabolic syndrome.

PCOS Phenotype

PCOS is heterogeneous. The Rotterdam classification defines four phenotypes: (A) hyperandrogenism + anovulation + PCO morphology; (B) hyperandrogenism + anovulation; (C) hyperandrogenism + PCO morphology with regular cycles; (D) anovulation + PCO with normal androgens. Women with phenotype A (classic PCOS) tend to have more severe insulin resistance and are less responsive to clomiphene. Those with phenotype D (normo‑androgenic anovulatory) often have higher success rates. Phenotyping therefore helps in counseling patients about expected outcomes.

Duration of Infertility and Prior Pregnancy

Longer duration of infertility (more than 3–4 years) is a negative prognostic factor. Women who have previously conceived naturally or with treatment have better cumulative pregnancy rates with clomiphene. Additionally, the presence of other infertility factors—such as male factor or tubal disease—should be ruled out before starting clomiphene, as they will lower the chance of success.

Monitoring and Management During Clomiphene Therapy

Baseline Assessment

Before initiating clomiphene, a thorough evaluation is essential. This should include a complete medical history, physical examination, confirmation of ovulatory dysfunction via menstrual history or progesterone levels, baseline pelvic ultrasound to exclude ovarian cysts or other pathology, and assessment of insulin resistance (e.g., fasting glucose/insulin) if indicated. A semen analysis for the male partner and hysterosalpingogram or other tubal patency test are recommended after 3–6 failed ovulatory cycles.

Cycle Monitoring

Monitoring aims to confirm ovulation, assess ovarian response, and detect complications such as OHSS or multiple pregnancies. The simplest approach is a mid‑luteal serum progesterone level greater than 3–5 ng/mL, which confirms ovulation occurred. Many clinicians perform a transvaginal ultrasound around cycle day 10–12 to measure follicle size and endometrial thickness. An endometrial thickness of less than 6–7 mm may indicate an anti‑estrogenic effect, which can be managed by reducing the clomiphene dose, using estrogen supplementation, or switching to letrozole. A single dominant follicle (18–24 mm) is desirable; three or more mature follicles increase the risk of multiple pregnancy and may warrant cycle cancellation or dose adjustment.

Duration of Therapy

Most guidelines recommend a maximum of six ovulatory cycles of clomiphene therapy because cumulative pregnancy rates plateau after 6–9 cycles. If conception has not occurred after six cycles, alternative treatments such as letrozole, gonadotropins, or IVF should be considered. Prolonged use beyond 12 cycles is not recommended due to a potential (though very rare) risk of ovarian cancer associated with cumulative exposure to ovulation‑inducing drugs.

Side Effects and Risks of Clomiphene Citrate

Common Side Effects

Approximately 10–20% of women experience side effects, including hot flashes, bloating, breast tenderness, nausea, dizziness, headache, and visual disturbances (blurred vision, diplopia, scotomata). Visual symptoms, while rare, require immediate discontinuation of the drug. Ovarian enlargement and discomfort may occur due to the formation of ovarian cysts; these are usually benign and resolve spontaneously.

Ovarian Hyperstimulation Syndrome (OHSS)

Severe OHSS is uncommon with clomiphene, occurring in less than 1% of cycles, but moderate OHSS can occur in about 5% of cycles. Symptoms include abdominal pain, nausea, vomiting, and weight gain due to ascites. Risk factors include polycystic ovaries, young age, low BMI, high AMH, and multiple follicular development. Ultrasound monitoring helps identify cycles at risk so that human chorionic gonadotropin (hCG) trigger can be withheld or coasting performed.

Multiple Pregnancy

Clomiphene is associated with a multiple pregnancy rate of approximately 5–10%, most commonly twins. Higher‑order multiples are rare (0.5–1%). This risk is lower than with gonadotropins but still significant. Multifetal gestation carries increased risks of preterm birth, preeclampsia, and neonatal complications. Careful monitoring and dose management are essential to minimize this risk.

Other Concerns

There has been debate regarding a possible link between clomiphene use and borderline ovarian tumors. Current evidence suggests that any association is likely due to the underlying infertility rather than the medication itself. Nevertheless, long‑term follow‑up studies are reassuring. Clomiphene is also known to thin the endometrium, which can be managed by lowering the dose or adding estrogen; if persistent, switching to letrozole is a viable alternative.

Alternatives and Adjunctive Therapies

Letrozole

As discussed, letrozole (2.5–7.5 mg daily for 5 days) has largely replaced clomiphene as first‑line therapy in many centers. It is an aromatase inhibitor that reduces estrogen production, thereby stimulating FSH release via reduced negative feedback. Letrozole yields higher live birth rates, lower multiple pregnancy rates (2–4%), and fewer side effects. It does not cause endometrial thinning and is particularly advantageous in women with a borderline response to clomiphene.

Metformin

Metformin improves insulin sensitivity and can induce ovulation in some women with PCOS, particularly those with glucose intolerance. Its role as an adjunct to clomiphene is modest—the combination of metformin plus clomiphene may improve ovulation rates but not live birth rates compared to clomiphene alone. The PPCOS II trial found no benefit of adding metformin to letrozole. Metformin is typically reserved for women with type 2 diabetes or prediabetes.

Gonadotropins

For women who are clomiphene‑resistant (no ovulation despite 150 mg), gonadotropins (subcutaneous injections of FSH and/or LH) are the next logical step. They are highly effective, with ovulation rates exceeding 90%, but require intensive monitoring to prevent OHSS and multiple pregnancy. The risk of twin pregnancy with gonadotropins is 15–20%, and higher‑order multiples are less common with careful low‑dose step‑up protocols. In vitro fertilization (IVF) with embryo transfer is an alternative to gonadotropin cycles, especially if tubal or male factors exist.

Lifestyle Modification

Lifestyle interventions remain the foundation of PCOS management. Even a modest weight loss of 5–10% can restore ovulation in about 30–50% of overweight women. Dietary changes emphasizing a low glycemic index, combined with regular exercise, improve insulin sensitivity and reduce hyperandrogenism. These measures should be implemented before and during any pharmacologic treatment.

Conclusion

Clomiphene citrate has been a reliable, inexpensive, and widely used ovulation‑inducing agent for PCOS‑related infertility for over 50 years. It effectively induces ovulation in the majority of anovulatory patients, with cumulative pregnancy rates approaching 50–60% over six cycles. However, its effectiveness is limited by anti‑estrogenic effects on the endometrium and cervix, leading to lower per‑cycle live birth rates compared to letrozole. The optimal candidate for clomiphene is a younger woman with normal or moderately elevated BMI, without insulin resistance, and with a favorable PCOS phenotype. Monitoring for ovulation, endometrial thickness, and cycle‑specific risks such as OHSS and multiple pregnancy is essential. Given current evidence, letrozole is now preferred as first‑line therapy, but clomiphene remains a valuable option, especially when letrozole is contraindicated or unavailable. Ultimately, individualized treatment—incorporating lifestyle changes, careful monitoring, and timely progression to more advanced therapies—offers the best chance for women with PCOS to achieve a healthy pregnancy.

For Further Reading